TxCELL appoints chief medical officer

TxCell, a French biotechnology company developing cell-based therapies using Type 1 T-regulatory lymphocytes for treating chronic inflammatory and autoimmune diseases, has appointed Miguel Forte to the newly created role of chief medical officer.

TxCell, a French biotechnology company developing cell-based therapies using Type 1 T-regulatory lymphocytes for treating chronic inflammatory and autoimmune diseases, has appointed Miguel Forte to the newly created role of chief medical officer.

Forte will take charge of the clinical department, clinical operations, clinical trials management and design. He joins the company from UCB, where he was vice-president, Global Medical Affairs Inflammation Worldwide. Prior to this, he spent two years at Nabi Pharmaceuticals as vice-president, Clinical, Medical and Regulatory Affairs Europe.






You may also like

Research & Development

TxCell names Lonza as its CAR-Treg cellular product manufacturer

Master Service Agreement signed between Lonza Pharma & Biotech and TxCell for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200)
Research & Development

TxCell Signs inlicensing agreement with Inserm Transfert for novel population of regulatory T cells

TxCell SA, a biotechnology company developing innovative, personalised cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, and Inserm Transfert, on behalf of Inserm, the Nantes University (Nantes, France) and the Nantes CHU, have announced the signature of an exclusive worldwide licensing agreement
Manufacturing

TxCell signs strategic agreement with MaSTherCell to manufacture cell therapy products

Company commits to an ambitious product development schedule with two discovery platforms
Manufacturing

TxCell to cut 26 jobs as it reviews its manufacturing strategy

Will focus on R&D and open a new laboratory close to its headquarters in Sophia Antipolis
Research & Development

TxCell raises around €8m in share placement

Will use proceeds to accelerate T-Cell developments and form partnerships with CMOs
Regulatory

TxCell puts pilot facility in France on partial hold

All production will move to a new commercial GMP manufacturing facility by 2018
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Subscribe now